|
|
Vaccine Detail
|
Mutant p53 Peptide Pulsed Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Mutant p53 Peptide Pulsed Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007427
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: p53
- mouse Trp53
gene engineering:
- Type: Recombinant protein preparation
- Description: (Svane et al., 2004)
- Detailed Gene Information: Click Here.
- Description: A cancer vaccine consisting of autologous dendritic cells which have been pulsed with a mutant p53 peptide. Vaccination with mutant p53 peptide pulsed dendritic cells may stimulate the host immune system to mount a cytotoxic T lymphocyte (CTL) response against tumor cells expressing mutant p53, resulting in tumor cell lysis. Many tumor cells overexpress mutant p53 proteins, resulting in the loss of apoptosis regulation and abnormal cell proliferation. (NCI04) (NCIT_C2540).
|
| Host Response |
|
|
| References |
NCIT_C2540: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C2540]
Svane et al., 2004: Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer immunology, immunotherapy : CII. 2004; 53(7); 633-641. [PubMed: 14985857].
|
|
